Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22154777 | 0.97 | CXCR4 (0.39) | CXCR4SMN1; SMN2ALDH1A1 | |
| SCHEMBL19840407 | 0.97 | CXCR4 (0.47) | CXCR4SMN1; SMN2ALDH1A1 | |
| SCHEMBL6012129 | 0.94 | — | — | |
| SCHEMBL20284982 | 0.94 | ALDH1A1 (0.44) | CXCR4SMN1; SMN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL939538 | 0.91 | CXCR4 (0.35) | CXCR4SMN1; SMN2ALDH1A1 | |
| SCHEMBL14789140 | 0.91 | ALDH1A1 (0.50) | CXCR4SMN1; SMN2ALDH1A1 | |
| SCHEMBL19841888 | 0.91 | CXCR4 (0.42) | CXCR4SMN1; SMN2ALDH1A1 | |
| SCHEMBL13770430 | 0.91 | ALDH1A1 (0.50) | CXCR4SMN1; SMN2ALDH1A1 | |
| SCHEMBL26460947 | 0.91 | ALDH1A1 (0.50) | CXCR4SMN1; SMN2ALDH1A1 | |
| SCHEMBL21390263 | 0.91 | ALDH1A1 (0.50) | CXCR4SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022100710-A1 | TYROSINE KINASE 2 (TYK2) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI) , INC. (CN) | 2022-05-19 | — | — | WO | disclosed |
| US-11225519-B2 | Treatment of cancers using anti-NKG2A agents | INNATE PHARMA (FR) | 2022-01-18 | — | — | US | disclosed |
| US-9662339-B2 | Benzodioxane inhibitors of leukotriene production for combination therapy | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-05-30 | — | — | US | disclosed |